Bioluminescence Assays and Reagents
Apexbio Technology LLC EZ Cap™ Firefly Luciferase mRNA, 100ug
EZ Cap™ Firefly Luciferase mRNA will express luciferase protein once entering cells, which is initially extracted from firefly Photinus pyralis. This enzyme catalyzes ATP-dependent D-luciferin oxidation and lead to yield chemiluminescence at about 560 nm wavelength. Firefly Luciferase is a frequently used bioluminescent reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.EZ Cap™ Firefly Luciferase mRNA is provided at a concentration of 1mg/ml. It is co-transcriptional capped by EZ Cap™ Reagent AG (3' OMe) (Catalog No.B8178) which generates a cap 1 structure with high efficiency. Cap 1 structure is more ideal for mammalian systems and possesses higher transcription efficiency than Cap 0 structure (ARCA and mCap). Other sizes are also available. Please inqury us for quote.
Apexbio Technology LLC EZ Cap™ Firefly Luciferase mRNA, 5x1mg
EZ Cap™ Firefly Luciferase mRNA will express luciferase protein once entering cells, which is initially extracted from firefly Photinus pyralis. This enzyme catalyzes ATP-dependent D-luciferin oxidation and lead to yield chemiluminescence at about 560 nm wavelength. Firefly Luciferase is a frequently used bioluminescent reporter for gene regulation and function study. It is applicable in assays for mRNA delivery, translation efficiency, cell viability and in vivo imaging etc.EZ Cap™ Firefly Luciferase mRNA is provided at a concentration of 1mg/ml. It is co-transcriptional capped by EZ Cap™ Reagent AG (3' OMe) (Catalog No.B8178) which generates a cap 1 structure with high efficiency. Cap 1 structure is more ideal for mammalian systems and possesses higher transcription efficiency than Cap 0 structure (ARCA and mCap). Other sizes are also available. Please inqury us for quote.
Abcam WAY 262611, Wnt pathway activator, 5MG
MW 318.4 Da, Purity >97%. Wnt pathway activator. Selectively inhibits Dkk1 with no GSK-3β inhibition. TCF-Luciferase agonist (EC₅₀ = 0.63 μM). Increases bone formation rate in vivo. Orally active.
The product is subject to the following: Abcam Restricted Use Statement